Related Experiment Video
Updated: Jun 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Advances in cholesterol-lowering interventions]
1Servicio de Endocrinología y Nutrición, Departamento de Medicina, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain. ascaso@uv.es
Insights
Statins are the primary choice for lowering cholesterol and preventing cardiovascular disease, significantly reducing events and mortality. Combination therapy may be needed if targets aren't met, with specific drug choices depending on individual lipid profiles.
Area of Science:
- Cardiology
- Pharmacology
- Epidemiology
Context:
- Established link between high cholesterol (total and LDL-C) and cardiovascular disease (CVD) morbidity/mortality.
- Statins demonstrate superior efficacy in reducing cardiovascular events and overall mortality compared to other lipid-lowering agents.
- Statins are generally safe, well-tolerated, and the first-line treatment for hypercholesterolemia and CVD prevention.
Purpose:
- Review the established role of statins in lipid management and cardiovascular risk reduction.
- Discuss the use of adjunctive therapies when statin monotherapy is insufficient.
- Address key unanswered questions regarding optimal LDL-C targets in secondary prevention and patient selection for primary prevention.
Summary:
- Epidemiological and intervention studies confirm statins' significant efficacy in reducing cardiovascular events and mortality.
- When treatment targets are unmet, combination therapy with other lipid-lowering drugs (e.g., resins, ezetimibe, fibrates) is indicated.
- Specific combinations (e.g., statins with nicotinic acid, fibrates, or omega-3) are considered for patients with low HDL-C and high triglycerides.
Impact:
- Provides a comprehensive overview of current lipid-lowering strategies, emphasizing statin therapy.
- Highlights the need for personalized treatment approaches and identifies areas for future research in cardiovascular disease prevention.
- Aims to guide clinicians in optimizing lipid management to diminish cardiovascular risk effectively.
Abstract:
Numerous epidemiological and prospective studies have shown a direct relationship between total cholesterol and low-density lipoprotein cholesterol (LDL-C) and cardiovascular disease (cardiovascular morbidity and mortality). In many intervention studies with more than 100,000 subjects, statins have shown a powerful and significant reduction of cardiovascular events and a decrease in cardiovascular and overall mortality, far superior to those produced by any other lipid-lowering group. Consequently statins are considered to be safe and well tolerated and are the first choice in the treatment of hypercholesterolemia and in cardiovascular disease prevention. If targets are not reached, other pharmacological groups must be associated (resins, nicotinic acid, ezetimibe, fibrates, etc.). Moreover, when hypercholesterolemia is associated with low concentrations of high-density lipoprotein (HDL)-cholesterol and high triglyceride levels, the association of statins with nicotinic acid, fibrates or omega-3 should be considered. Some questions remain to be answered: what LDL-C levels are desirable in secondary prevention? Which individuals might benefit from treatment in primary prevention? Which lipid-lowering drug is the most suitable to combine with statins and diminish cardiovascular risk in each situation? The present article reviews these important points.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures
Pharmacogenomics: Identification of New Drug Targets
Lipids: Dietary Sources and Requirements
